Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients.Adoptive cell transfer and checkpoint blockade therapies in particular both demons...Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients.Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective,even in previously refractory late stage disease.Such developments,together with advances in technology,have strongly encouraged revisiting the concept of neoantigen vaccines.Here we introduce basic ideas in the field to allow investigators from diverse backgrounds to understand these developments,grasp current issues,and contribute to further progress.展开更多
基金This work was supported by a National Basic Research Program of China(973 Program,No.2014CB745202)the Shenzhen Peacock Team Project(No.KQTD2015033117210153)+1 种基金the Shenzhen Science and Technology Innovation Committee Basic Science Research Grants(No.JCYJ20170413154523577,No.JCYJ20150629151046896)the Guangdong Natural Science Funds for Distinguished Young Scholar Grant(No.S2013050016987).
文摘Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients.Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective,even in previously refractory late stage disease.Such developments,together with advances in technology,have strongly encouraged revisiting the concept of neoantigen vaccines.Here we introduce basic ideas in the field to allow investigators from diverse backgrounds to understand these developments,grasp current issues,and contribute to further progress.
